Sissetulev kiriAvalik
Pöördumine
Sotsiaalministeerium · 27. veebruar 2026
- Viit
- 1.4-2/538-1
- Registreeritud
- 27. veebruar 2026
- Dokumendi liik
- Sissetulev kiri
- Adressaat
- Chief Pharmaceutical Inspectorate
- Saabumis/saatmisviis
- e-post
- Funktsioon
- 1.4 EL otsustusprotsess ja rahvusvaheline koostöö
- Sari
- 1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
- Toimik
- 1.4-2/2026
- Vastutaja
- Kristiin Mikko (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Rahvatervishoiu osakond)
- Lahendamise tähtaeg
- 16. märts 2026
Failid
Sisu (failidest)
Saatja: "Wachełko Olga" <[email protected]>
Saaja: "Info - SOM" <[email protected]>, [email protected]
Teema: Inquiry regarding the legal framework in your country
Kuupäev: 2026-02-27 11:22
Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.
Dear Competent Authorities,
We are contacting you as your institution is listed among the Competent
National Authorities under the International Drug Control Treaties (UNODC,
2024).
As part of the legislative work currently being undertaken in our country,
we are conducting a comparative analysis of regulatory frameworks applicable
to medical cannabis in other countries. In this context, we would highly
appreciate your assistance in clarifying the legal framework in force in
your country.
In particular, we would be grateful for information on the following issues:
1. Which operators are authorised to cultivate cannabis for medical
purposes? May such authorisation be granted to both public and private
sector entities, and under what general conditions?
2. Which government authority is competent to grant licences or permits for
the cultivation of cannabis (other than industrial hemp)? Additionally,
which authority is responsible for supervising and verifying compliance of
the cultivation with the relevant legal requirements? Furthermore, is
oversight of the entire process (including the distribution of medical
cannabis to pharmacies or hospitals) entrusted to a single supervisory
authority, or is responsibility divided among different institutions?
3. What is the maximum permissible content of THC and THC-A in preparations
and products derived from industrial hemp in order for them to remain lawful
under the applicable legislation? Furthermore, is home cultivation for
personal use permitted under national law?
Thank you in advance for your cooperation. We look forward to your response.
Sincerely,
CHIEF PHARMACEUTICAL INSPECTORATE
Controlled Substances Division
Pharmaceutical Supervision Department
Olga Wachełko
Senior Specialist
12 Senatorska St., 00-082 Warsaw
Phone +48 22 44 10 709
<mailto:[email protected]> [email protected]
<http://www.gif.gov.pl/> www.gif.gov.pl